Prophylactic TT is recommended in patients with MTC who have an RET germline mutation and the resulting multiple endocrine neoplasia type 2A (MEN2A) or multiple endocrine neoplasia type 2A (MEN2B) syndrome [31]. This evidence concerns the gene RET and multiple endocrine neoplasia type 2B.